Targeting IDH in Low-Grade Glioma
Elizabeth B. Claus, Roel G.W. Verhaak
Abstract
This editorial describes the science behind a trial of vorasidenib, an inhibitor of variant isocitrate dehydrogenase, to treat grade 2 glioma.
Topics & Concepts
Isocitrate dehydrogenaseGliomaMedicineIDH1OncologyCancer researchInternal medicineGeneticsEnzymeGeneBiologyBiochemistryMutationGlioma Diagnosis and TreatmentCancer, Hypoxia, and MetabolismPancreatic and Hepatic Oncology Research